1820563-84-5
Chemical Structure
NOTA-AE105
- CAS No.: 1820563-84-5
- Formula:C72H102N16O20
- Molecular Weight:1511.68
InChIKey: QYDKPVWTZOEIPR-WKDKGDAESA-N
SMILES: O=C(N[C@@H](CO)C(O)=O)[C@@H](NC([C@H](CC(C)C)NC([C@@H](NC([C@@H](CCCNC(N)=N)NC([C@@H](CO)NC([C@H](CC1=CC=CC=C1)NC([C@@H](NC([C@H](CC(O)=O)NC(CN(CCN2CC(O)=O)CCN(CC2)CC(O)=O)=O)=O)CC3CCCCC3)=O)=O)=O)=O)CC(C=C4)=CC=C4O)=O)=O)CC5=CNC6=CC=CC=C56
Biological Activity: NOTA-AE105 is a uPAR-targeting PET imaging ligand. NOTA-AE105 can be radiolabeled with 64Cu and 68Ga. NOTA-AE105 binds to the urokinase-type plasminogen activator receptor, thereby enabling PET imaging of uPAR expression in tumor tissues. NOTA-AE105 can be used for research on head and neck squamous cell carcinoma, breast cancer, prostate cancer, bladder cancer, and glioblastoma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NOTA-AE105 | 98.99% | NOTA-AE105 is a uPAR-targeting PET imaging ligand. NOTA-AE105 can be radiolabeled with 64Cu and 68Ga. NOTA-AE105 binds to the urokinase-type plasminogen activator receptor, thereby enabling PET imaging of uPAR expression in tumor tissues. NOTA-AE105 can be used for research on head and neck squamous cell carcinoma, breast cancer, prostate cancer, bladder cancer, and glioblastoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Risør LM, et al. Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with F-FDG PET/CT: A Single-Center Prospective Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2022 Aug;63(8):1169-1176. [Content Brief]
- [2]. Skovgaard D, et al. Safety, Dosimetry, and Tumor Detection Ability of Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017 Mar;58(3):379-386.
- [3]. Persson M, et al. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Feb;57(2):272-8.
